The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease
Open accessAbstract
Minocycline is broadly protective in neurologic disease models featuring cell death and is being evaluated in clinical trials. We previously demonstrated that minocycline-mediated protection against caspase-dependent cell death related to its ability to prevent mitochondrial cytochrome c release. These results do not explain whether or how minocycline protects against caspase-independent cell death. Furthermore, there is no information on whether Smac/Diablo or apoptosis-inducing factor might play a role in chronic neurodegeneration. In a striatal cell model of Huntington's disease and in R6/2 mice, we demonstrate the association of cell death/disease progression with the recruitment of mitochondrial caspase-independent (apoptosis-inducing factor) and caspase-dependent (Smac/Diablo and cytochrome c ) triggers. We show that minocycline is a drug that directly inhibits both caspase-independent and -dependent mitochondrial cell death pathways. Furthermore, this report demonstrates recruitment of Smac/Diablo and apoptosis-inducing factor in chronic neurodegeneration. Our results further delineate the mechanism by which minocycline mediates its remarkably broad neuroprotective effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289
Self-citationMolecular characterization of mitochondrial apoptosis-inducing factor
Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., et al. (1999) · Nature · doi:10.1038/17135 · Cited by 4,060
Du, C., Fang, M., Li, Y., Li, L., & Wang, X. (2000) · Cell · doi:10.1016/s0092-8674(00)00008-8 · Cited by 3,513
Self-citationMangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor
Yu, S.-W., Wang, H., Poitras, M. F., Coombs, C., Bowers, W. J., Federoff, H. J., Poirier, G. G., Dawson, T. M., & Dawson, V. L. (2002) · Science · doi:10.1126/science.1072221 · Cited by 1,826
Endonuclease G is an apoptotic DNase when released from mitochondria
Li, L. Y., Luo, X., & Wang, X. (2001) · Nature · doi:10.1038/35083620 · Cited by 1,787
Self-citationWu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y. S., Ona, V., Li, M., Sarang, S., Liu, A. S., Hartley, D. M., Wu, D. C., et al. (2002) · Nature · doi:10.1038/417074a · Cited by 1,067
Self-citationChen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K. B., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,051
Self-citation
Cited by
Minocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Self-citationMcCoy, M. K., & Tansey, M. G. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-45 · Cited by 847
Mitochondrial calcium and the permeability transition in cell death
Lemasters, J. J., Theruvath, T. P., Zhong, Z., & Nieminen, A.-L. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2009.06.009 · Cited by 654
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., Hilton, J. F., Spitalny, G. M., MacArthur, R. B., Mitsumoto, H., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70270-3 · Cited by 649
Brain Tissue Responses to Neural Implants Impact Signal Sensitivity and Intervention Strategies
Kozai, T. D. Y., Jaquins-Gerstl, A. S., Vazquez, A. L., Michael, A. C., & Cui, X. T. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn500256e · Cited by 622
Karimi-Abdolrezaee, S., Eftekharpour, E., Wang, J., Morshead, C. M., & Fehlings, M. G. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4184-05.2006 · Cited by 601
Hüttemann, M., Pecina, P., Rainbolt, M., Sanderson, T. H., Kagan, V. E., Samavati, L., Doan, J. W., & Lee, I. (2011) · Mitochondrion · doi:10.1016/j.mito.2011.01.010 · Cited by 522
The Promise of Minocycline in Neurology
Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518
Stirling, D. P., Khodarahmi, K., Liu, J., McPhail, L. T., McBride, C. B., Steeves, J. D., Ramer, M. S., & Tetzlaff, W. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5275-03.2004 · Cited by 507
Microglia Biology in Health and Disease
Garden, G. A., & Möller, T. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9015-5 · Cited by 496
Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling
Hong, S. J., Dawson, T. M., & Dawson, V. L. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.03.005 · Cited by 463
Minocycline and Neurodegenerative Diseases
Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447
Minocycline treatment in acute stroke: An open-label, evaluator-blinded study
Lampl, Y., Boaz, M., Gilad, R., Lorberboym, M., Dabby, R., Rapoport, A., Anca-Hershkowitz, M., & Sadeh, M. (2007) · Neurology · doi:10.1212/01.wnl.0000277487.04281.db · Cited by 440
Griffin, M. O., Fricovsky, E., Ceballos, G., & Villarreal, F. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00047.2010 · Cited by 413
Huntington's disease: from pathology and genetics to potential therapies
Imarisio, S., Carmichael, J., Korolchuk, V., Chen, C.-W., Saiki, S., Rose, C., Krishna, G., Davies, J. E., Ttofi, E., Underwood, B. R., et al. (2008) · Biochemical Journal · doi:10.1042/bj20071619 · Cited by 409
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Palazuelos, J., Aguado, T., Pazos, M. R., Julien, B., Carrasco, C., Resel, E., Sagredo, O., Benito, C., Romero, J., Azcoitia, I., et al. (2009) · Brain · doi:10.1093/brain/awp239 · Cited by 382
Teng, Y. D., Choi, H., Onario, R. C., Zhu, S., Desilets, F. C., Lan, S., Woodard, E. J., Snyder, E. Y., Eichler, M. E., & Friedlander, R. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306239101 · Cited by 335
Self-citationMitochondrial association of alpha-synuclein causes oxidative stress
Parihar, M. S., Parihar, A., Fujita, M., Hashimoto, M., & Ghafourifar, P. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7589-1 · Cited by 330
Bosco, A., Inman, D. M., Steele, M. R., Wu, G., Soto, I., Marsh-Armstrong, N., Hubbard, W. C., Calkins, D. J., Horner, P. J., & Vetter, M. L. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1337 · Cited by 323
Choi, Y., Kim, H.-S., Shin, K. Y., Kim, E.-M., Kim, M., Kim, H.-S., Park, C. H., Jeong, Y. H., Yoo, J., Lee, J.-P., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301377 · Cited by 289
The age-related attenuation in long-term potentiation is associated with microglial activation
Griffin, R., Nally, R., Nolan, Y., McCartney, Y., Linden, J., & Lynch, M. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04165.x · Cited by 282
Minocycline as a Neuroprotective Agent
Stirling, D. P., Koochesfahani, K. M., Steeves, J. D., & Tetzlaff, W. (2005) · The Neuroscientist · doi:10.1177/1073858405275175 · Cited by 279
Chen, C., Jiang, P., Xue, H., Peterson, S. E., Tran, H. T., McCann, A. E., Parast, M. M., Li, S., Pleasure, D. E., Laurent, L. C., et al. (2014) · Nature Communications · doi:10.1038/ncomms5430 · Cited by 219
Scholz, R., Sobotka, M., Caramoy, A., Stempfl, T., Moehle, C., & Langmann, T. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0431-4 · Cited by 177
The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies
Bauer, P. O., & Nukina, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06302.x · Cited by 178
Pasquini, L. A., Calatayud, C. A., Bertone Uña, A. L., Millet, V., Pasquini, J. M., & Soto, E. F. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9165-0 · Cited by 176
Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation
Shao, J., Welch, W. J., DiProspero, N. A., & Diamond, M. I. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00079-08 · Cited by 171
Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts
Fellner, L., Jellinger, K. A., Wenning, G. K., & Stefanova, N. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0833-z · Cited by 162
“Minocycline is a tetracycline antibiotic that crosses the blood–brain barrier and has anti-inflammatory along with its anti-apoptotic activity [251].”
BackgroundHigh MMP-9 activity levels in fragile X syndrome are lowered by minocycline
Dziembowska, M., Pretto, D. I., Janusz, A., Kaczmarek, L., Leigh, M. J., Gabriel, N., Durbin‐Johnson, B., Hagerman, R. J., & Tassone, F. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36023 · Cited by 161
“…seems to target molecular factors important for neuroprotection as demonstrated by effective treatment in animalmodels ofAlzheimer disease [Choi et al., 2007], Parkinson disease [Wu et al., 2002], Amyotrophic Lateral Sclerosis (ALS) [Kriz et al., 2002], and Huntington disease [Wang et al., 2003].”
BackgroundClinical Potential of Minocycline for Neurodegenerative Disorders
BLUM, D., CHTARTO, A., TENENBAUM, L., BROTCHI, J., & LEVIVIER, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.012 · Cited by 157
Kozai, T. D. Y., Li, X., Bodily, L. M., Caparosa, E. M., Zenonos, G. A., Carlisle, D. L., Friedlander, R. M., & Cui, X. T. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.08.006 · Cited by 136
Self-citationMinocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage
Morimoto, N., Shimazawa, M., Yamashima, T., Nagai, H., & Hara, H. (2005) · Brain Research · doi:10.1016/j.brainres.2005.02.062 · Cited by 137
The Potential of Minocycline for Neuroprotection in Human Neurologic Disease
Zemke, D., & Majid, A. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000150867.98887.3e · Cited by 125
Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice
Stack, E. C., Smith, K. M., Ryu, H., Cormier, K., Chen, M., Hagerty, S. W., Del Signore, S. J., Cudkowicz, M. E., Friedlander, R. M., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.11.002 · Cited by 114
“In fact, minocycline has been shown to inhibit caspase-dependent and caspase-independent cell death mechanisms [12,14,16].”
BackgroundSelf-citationAnti-Inflammatory Impact of Minocycline in a Mouse Model of Tauopathy
Garwood, C. J., Cooper, J. D., Hanger, D. P., & Noble, W. (2010) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2010.00136 · Cited by 106
Khodaie-Ardakani, M.-R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Rezaei, F., Salehi, B., Yekehtaz, H., Ashrafi, M., et al. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.051 · Cited by 104
Astrocyte–neuron interplay in maladaptive plasticity.
Papa, M., De Luca, C., Petta, F., Alberghina, L., & Cirillo, G. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.01.010 · Cited by 104
Inflammation in transgenic mouse models of neurodegenerative disorders
Schwab, C., Klegeris, A., & McGeer, P. L. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.013 · Cited by 97
The Therapeutic Role of Minocycline in Parkinson’s Disease
Cankaya, S., Cankaya, B., Kilic, U., Kilic, E., & Yulug, B. (2019) · Drugs in Context · doi:10.7573/dic.212553 · Cited by 93
Minocycline treatment for HIV-associated cognitive impairment: Results from a randomized trial
Sacktor, N., Miyahara, S., Deng, L., Evans, S., Schifitto, G., Cohen, B. A., Paul, R., Robertson, K., Jarocki, B., Scarsi, K., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822f0412 · Cited by 87
Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects
Chen, Y., Won, S. J., Xu, Y., & Swanson, R. A. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666131228203906 · Cited by 81
Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics
Jia, Q., Li, S., Li, X.-J., & Yin, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1088124 · Cited by 70
“R6/2 mice were administered with the anti-inflammatory tetracycline minocycline showed improvements in behavioral and neuropathological deficits (89, 90), which is also supported by an excitotoxic rat model of HD (91).”
Quintero, E. M., Willis, L., Singleton, R., Harris, N., Huang, P., Bhat, N., & Granholm, A.-C. (2006) · Brain Research · doi:10.1016/j.brainres.2006.03.104 · Cited by 58
Baptiste, D. C., Hartwick, A. T. E., Jollimore, C. A. B., Baldridge, W. H., Seigel, G. M., & Kelly, M. E. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.001081 · Cited by 55
Minocycline Protects Dopaminergic Neurons Against Long-Term Rotenone Toxicity
Radad, K., Moldzio, R., & Rausch, W.-D. (2010) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100009690 · Cited by 30
Minocycline Mitigation of Tremor Syndrome and Defect of Cognitive and Balance Induced by Harmaline
Department of Physiology, P. R. C., Maneshian, M., Nasirinezhad, F., Department of Physiology, P. R. C., Mohammadi, F., Intracellular Recording Lab, N. R. C., Behzadi, M., Intracellular Recording Lab, N. R. C., Asadi-Shekaari, M., Intracellular Recording Lab, N. R. C., et al. (2021) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.12.2.1980.1 · Cited by 4
Metadata
- Authors
- Wang, X., Zhu, S., Drozda, M., Zhang, W., Stavrovskaya, I. G., Cattaneo, E., Ferrante, R. J., Kristal, B. S., & Friedlander, R. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-08-20
- Volume
- 100
- Issue
- 18
- Pages
- 10483-10487
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2086129284
- Cited by
- 407
- References
- 32
- FWCI
- 10.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.